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Abstract
The Boost Brittle Bones Before Birth (BOOSTB4) clinical trial is investigating the safety and efﬁcacy of transplanting fetal
derived mesenchymal stromal cells (MSCs) prenatally and/or in early postnatal life to treat severe Osteogenesis Imperfecta
(OI). This study aimed to explore stakeholder views to understand perceived beneﬁts or concerns, identify ethical issues and
establish protocols for support and counselling. Semi-structured qualitative interviews were conducted with three groups; 1.
Adults affected with OI, with and without children, and parents of children affected with OI; 2. Health professionals who
work with patients with OI; 3. Patient advocates from relevant patient support groups. Interviews were digitally recorded,
transcribed verbatim and analysed using thematic analysis. Interviews with 56 participants revealed generally positive views
towards using fetal MSC transplantation to treat OI. Early treatment was considered advantageous for preventing fractures
and reducing severity and could bring psychological beneﬁts for parents. Common concerns were procedure safety, short/
long-term side effects and whether transplantation would be effective. Difﬁculties inherent in decision-making were
frequently discussed, as treatment efﬁcacy is unknown and, by necessity, parents will make decisions at a time when they are
vulnerable. Support needs may differ where there is a family history of OI compared to an unexpected diagnosis of OI.
Explaining fetal MSC transplantation in a way that all parents can understand, clear expectation setting, psychological
support and time for reﬂection during the decision-making process will be crucial to allow parents to make informed
decisions about participation in the BOOSTB4 clinical trial.
Introduction
Osteogenesis Imperfecta (OI) is a rare metabolic bone
disorder that affects ~1 in 20,000 births [1–3]. Common
features include bone fragility, osteopenia, short stature,
atypical skeletal development, brittle teeth, hearing loss and
hypermobile joints [1, 2]. Variants in the COL1A1 and
COL1A2 genes that either reduce the amount of collagen or
impact on collagen structure are causal in 85–90% of cases
[4]. OI has been classiﬁed as mild (type 1), moderate (type
4), severe (type 3) or lethal (type 2) [5]. OI is a hetero-
geneous condition and severity varies widely, including
between family members with the same genetic variant [6].
Severe forms can sometimes be identiﬁed before birth when
ultrasound detects fractures, reduced fetal growth or bowing
of the limbs.
There are no curative interventions for OI. Treatment
options focus on reducing fractures and deformity, provid-
ing relief from pain and improving mobility and day-to-day
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function [6]. Bisphosphonates are often offered when chil-
dren have moderate to severe OI as they increase bone
mineral density and improve bone strength and, as a result,
reduce fracture risk and bone pain [7]. Surgery, such as
intramedullary rodding, maintains bony alignment and
reduces fracture risks when long bones are bowed or if
fractures are recurrent [6]. Physical and occupational ther-
apy are also commonly used to help with mobility and
function [8].
Transplantation of fetal mesenchymal stem cells (MSCs)
is a new approach to treating OI that, although it will not cure
the condition, does have the potential to modify severity [9,
10]. As OI can cause damage early in fetal life, prenatal or
early post-natal (ﬁrst year of life) stem cell transplantation
(SCT) could help to ameliorate the disease process at a time
of rapid skeletal development and before additional pathol-
ogy occurs as a result of fractures. To date clinical experience
with SCT for OI is limited, and further studies are needed
[10, 11]. The Boost Brittle Bones Before Birth (BOOSTB4)
Phase I/II clinical trial will examine the safety and, efﬁcacy
of SCT for severe OI. The aim of our study was to explore
the views and attitudes of key stakeholders towards SCT and
the proposed BOOSTB4 clinical trial.
Materials and methods
A qualitative approach using one-to-one semi-structured
interviews was used to enable an in-depth exploration of
stakeholder views. NHS Research Ethics Committee
approval was obtained (16/NS/0084).
Sampling and recruitment
Three participant groups were recruited; (1) Adults affected
with OI, with and without children affected with OI, and
parents of children affected with OI, who were not affected
with OI themselves (“patients and parents”); (2) health pro-
fessionals; and (3) patient advocates from relevant support
groups. Patients and parents were recruited through four
paediatric (three in England one in Scotland) and one adult
OI specialist service (in England). Potential participants who
met the inclusion criteria of being 16 years and over and able
to communicate in English were identiﬁed by the clinical
team. The participant information was either sent by mail to
potential participants or provided at clinic appointments. An
advertisement was placed on the Brittle Bone Society (UK
patient support group for families with OI) website and
Facebook page. Potential participants were asked to contact
MH if interested in participating or, if attending a clinic, they
could complete a “consent to contact” form and MH then
contacted them by email or telephone. Health professionals
and patient advocates were identiﬁed by the research team
with input from the OI specialist services and invited to
participate by MH via email.
Information provided about fetal MSC
transplantation and the BOOSTB4 clinical trial
A BOOSTB4 Fact Sheet, developed by MH and reviewed
by the multi-disciplinary research team, included the fol-
lowing key information about the planned BOOSTB4
clinical trial; 1. The trial will look at the safety and efﬁcacy
of SCT initiated during pregnancy or shortly after birth. 2.
Early treatment was chosen to support engraftment, mini-
mise risks of immunosuppression and because OI can cause
damage very early in life. 3. Trial eligibility will be limited
to severe forms of OI resulting from speciﬁc genetic var-
iants. 4. Prenatal SCT has a 1% risk of miscarriage or pre-
term birth. 5. SCT will be given several times over two
years. 6. Fetal MSCs are obtained when women choosing to
have a termination of pregnancy for personal reasons in the
ﬁrst trimester agree to donate fetal cells for research. 7. The
number of children with OI previously treated with SCT is
very small.
Interviews
Semi-structured interviews were conducted face-to-face
or via telephone by MH. Interviews were designed to last
30–40 min. Demographic questions included age, education
level, ethnicity and number of children. The interview guide
explored four topic areas; 1. Experiences of living with OI
or working with families affected by OI. 2. Views on current
treatments for OI. 3. Views on using SCT to treat OI. 4.
Support and information needs for decision making. Findings
from the ﬁrst two topic areas will be reported separately.
Data analysis
Interviews were digitally recorded, transcribed verbatim and
anonymised. Pseudonyms were assigned to each participant.
Data were analysed by MH and CL using the principles of
thematic analysis [12]. MH and CL are experienced quali-
tative researchers with no previous research experience in OI,
fetal therapy or SCT, which allowed a critical distance from
the research topic. NVivo10 (QSR International, Pty Ltd,
Australia) was used to facilitate analysis. Transcripts were
coded into meaningful units of text. Codes were then
grouped into broader categories and themes that were pro-
gressively reviewed and redeﬁned. The three participant
groups were initially treated as separate data sets. Emerging
themes were then compared and ultimately combined. MH
coded all transcripts and CL coded a sub-set (10%) of tran-
scripts independently to ensure inter-rater reliability. No
substantial differences in interpretation occurred.
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Results
Interviews were conducted with 56 participants; 25 patients
and parents, two patient advocates and 29 health profes-
sionals. Nine patients and parents were recruited through
the Brittle Bone Society and 16 through OI specialist ser-
vices. As recruitment combined invitations and advertise-
ments, a response rate could not be calculated. Two patient
advocates were invited to participate, and both accepted. Of
43 health professionals invited to participate, 29 agreed
(response rate: 67%). One health professional is a member
of the BOOSTB4 research team. Interviews were conducted
between 30/09/2016 and 15/02/2018, 19 in person and
36 by phone. Interviews lasted between 15 and 56 min
(median= 30 min). Participant characteristics are described
in Tables 1 and 2. Three overarching themes arose from
the interviews; “potential beneﬁts”, “concerns” and “deci-
sion making”.
Potential beneﬁts
Modifying the severity of OI will have clinical and
psychosocial beneﬁts
Participants spoke about OI as a condition that impacts on
all areas of life and felt that if SCT was successful the result
would be wide-ranging clinical and psychosocial beneﬁts












Fetal medicine specialist 3
Genetic counsellor 2
Nurse specialist (paediatric care) 3
Nurse specialist (adolescent/adult care) 1
Occupational therapist (paediatric care) 2




Physiotherapist (paediatric care) 5
Psychologist (paediatric care) 1
Rheumatologist (adolescent/adult) 2




































Number of children with OI
None 9
One child with OI 10
Two children with OI 5
Three children with OI 1
Self-described OI type of self or child
Type 1 or Mild 16
Type 4 or Moderate 1
Type 3 or Severe 7
Recruited from
Brittle Bone Society 9
OI specialist service 16
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for the child and their family. The potential clinical beneﬁts
most commonly highlighted were; a reduction in the num-
ber of fractures, fewer bone deformities and improved
growth. There was also hope that SCT could beneﬁt chronic
pain, tiredness and dental problems. Participants felt that
clinical improvements would lead to multiple psychosocial
beneﬁts for children as fewer hospital visits for fractures
and a reduced need for surgery would mean more time at
school and greater involvement in family and social activ-
ities (Table 3: Quote 1). In addition, improvements in
function would allow greater independence as children
would be “less dependent on wheelchairs or other people”.
Many commented that quality of life would be improved
and that SCT could help the child to be “stronger and
healthier and happier” and have a more “normal life.”
Possible psychosocial beneﬁts for parents were fre-
quently discussed. Some participants noted that reducing
the likelihood of fracturing would decrease the emotional
toll of OI as there wouldn’t be the same fear of fractures and
distress at seeing the child in pain (Table 3: Quote 2). In
addition, some participants suggested that if SCT led par-
ents to view their child as less fragile then they would have
greater conﬁdence when handling their child and that this
could have a positive impact on bonding (Table 3: Quote 3).
Early interventions are viewed positively
Participants valued that treatment could begin early in life.
As fractures can occur in utero, during the birth process or
soon afterwards, it was viewed as being particularly bene-
ﬁcial to intervene during pregnancy (Table 3: Quote 4).
Possible psychological beneﬁts for parents included SCT
being an additional option to consider at the time of diag-
nosis that would offer parents some “hope”. Starting treat-
ment during pregnancy or shortly after birth may also
alleviate some of the feelings of anxiety and powerlessness
that can occur when OI is diagnosed (Table 3: Quote 5).
Some health professionals also felt that offering SCT in
pregnancy would be valued by parents who would not
consider termination of pregnancy as “they could improve
the quality of life” of the child.
Positive impacts on starting a family when you have
moderate/severe OI yourself
Several adults affected with OI commented that they did not
want to pass OI to their child. SCT was seen to offer an
additional option to consider when starting a family that
may allow having a child to be viewed more positively
(Table 3: Quote 6). Some participants noted that it is dif-
ﬁcult to care for a child with OI when you have OI yourself
(Table 3: Quote 7) and it may be possible to take a more
active role in parenting if SCT can reduce the severity of the
child’s OI.
Reduce the need for bisphosphonates
Although most participants spoke positively about bispho-
sphonate treatment for children with OI and valued the
observed improvements to fracture rates, pain and tiredness,
they also noted that many children “struggle” with cannu-
lation and the frequency of treatments can be “burdensome
for families”. Consequently, SCT would be welcomed if
improvements in bone strength meant that bisphosphonates
could be given at less frequently or not be needed at all.
Research about OI is important
Participants were very positive that “innovative” research
on new treatments for rare conditions such as OI were being
undertaken (Table 3: Quote 8). Some health professionals
commented that the evaluation of SCT as a treatment for OI
may ultimately lead to similar therapies for skeletal dys-
plasias and other rare diseases which “could be a huge leap
forward”.
Concerns
The stem cells are fetal in origin
Some participants, from both the patients and parents and
health professional groups, commented that they personally
felt “uncomfortable” or “worried” about the fetal origin of
the stem cells. Reasons included; not agreeing with termi-
nation of pregnancy, which was sometimes linked to the
person’s religious beliefs, views around when a “person
becomes a person”, concern that supporting the use of fetal
cell therapies may encourage more terminations as “people
would more easily choose abortion, thinking that [the stem
cells] could be used for something good” and the fetus is
unable to give consent. Some of these participants said that
their concern about the origin of the cells was not “clear
cut” or said that they were “slightly on the fence” as they
could see that some good could come out of using the cells.
The majority of participants reported not having any ethical
concerns about the fetal origin of the stem cells and felt that
if the mother had already made the decision to terminate
and had given informed consent to donate the cells, then
this was an “opportunity for something good to come out of
a bad situation”. It was acknowledged that the fetal origin of
the cells could be an issue for some people. One health
professional noted that some parents may be “conﬂicted” as
they have concerns about the origin of the cells, but also
want their child to be well.
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Table 3 Participant quotations to support themes
Quote Number Quotation
1 “They’re not going to need to spend as much time in hospitals or sort of in casts and things like that… It would have
big implications for families being able to access more schooling and more social time.”
Luke, health professional from an OI specialist team
2 “…if there was a treatment that reduced a risk of fractures and then, then we would certainly be open to looking at it
and considering it. Because I think what’s, what’s really hard about OI is, is that constant fear of fracturing”
Carmel, parent of a child with OI
3 “I think it would have a massive positive effect on bonding, development, everything else if you just knew that the
chances of them fracturing was going to be less, I think you’d feel a lot more robust about it.”
Sally, health professional from an OI specialist team
4 “With the more severe types, obviously as soon as they start to move around in the womb they fracture so anything
that could reduce this risk is good.”
Mary, adult with OI, who has a child with OI
5 “You feel entirely powerless with a genetic issue. So it would be amazing to be able to have and feel like you could
inﬂuence or to improve, improve the situation”
Annie, parent of a child with OI
6 “I was quite overjoyed. I think when I ﬁrst started reading about [SCT] because I was thinking instantly about my
family, my future family and how that would be hugely beneﬁcial.”
Nathan, adult with OI
7 “…if I did have a child that has multiple breaks and I have got the condition myself it would be very difﬁcult for me on
a practical side moving a child that’s got lots of breaks.”
Mia, adult with OI
8 “I think it’s really exciting that, you know, something new for the OI community and yeah could potentially be really
life changing for people”
Lily, adult with OI
9 “I think you’d probably ask whether you could introduce any other diseases or other conditions through doing that”
Sam, parent of a child with OI
10 “I would say after pregnancy just purely because of the risk of miscarriage”
Jill, adult with OI
11 “Obviously there’s a risk that there’ll be no difference or things might not go, you know, they may even get worse.”
Ben, health professional from an OI specialist team
12 “How many children have had it already? How much has this been tested? Because I think you’d have to be very brave
to, you know, be one of the ﬁrst”
Olivia, adult with OI who has a child with OI
13 “Stem cells are in the paper all the time, ‘magic new therapy’. And again I do worry a little bit about some families
which will go ahead and say ‘yes, yes’ and think that possibly, the outcome may be different than what it will actually
be.”
Julie, health professional from an OI specialist team
14 “I think going through the process of treatment and then not having the outcome you wanted would be really, really
difﬁcult.”
Laura, adult with OI
15 “We want to do everything we can and to help to make sure that they’re making an informed decision that isn’t just a,
sort of, reaction to the situation that they’re in, is really challenging because you can say, yeah, that the acute grief will
make them quite vulnerable to maybe making a decision that they wouldn’t make in a different setting”
Emma, genetic counsellor
16 “If I put myself in the shoes of when we were pregnant… if I didn’t have an OI child I think I might be reluctant to do
something, I’d be honest, but if I had an OI child my God I’d be wanting to try everything… And I think it will be
quite hard for someone who doesn’t fully understand what OI means.”
Alex, parent of a child with OI
17 “I would have had the treatment bar the risks, bar wherever the stem cells are from or I would have given it a go and I
would have had to because I couldn’t in six months’ time be sitting by that baby in the hospital with two cracked
femurs because how could I then say to myself I did everything I could for you because I didn’t take that risk.”
Ameenah, adult with OI who has a child with OI
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Possible risks to the child and mother
All participants wanted to be conﬁdent that the stem cells
were as safe as possible for both child and mother and
information about possible short- and long-term side effects
of having SCT would be important in decision making.
Some also commented that parents would want to be con-
ﬁdent that the stem cells had been tested to prevent diseases
being passed from the donor (Table 3: Quote 9).
The quoted 1% risk of miscarriage or pre-term birth
associated with prenatal SCT was noted as a concern by
most participants. For some in the patients and parents
group this risk was viewed as unacceptable and they said
that they would prefer to wait until after the baby was born
to consider SCT (Table 3: Quote 10). For other participants
the risk of miscarriage was discussed as a factor that would
need to be carefully weighed against the possible beneﬁts of
initiating SCT during pregnancy.
The uncertainty associated with a very new treatment
approach
The fact that SCT is a new approach for treating OI was
discussed as a concern by some participants who high-
lighted the current uncertainties; SCT may not work as
expected (Table 3: Quote 11), there may be side-effects or
complications, including some that may not have been
anticipated, and we do not know the long-term implications.
Several participants commented that you would have to be
brave to try a new treatment and some felt that parents may
be anxious about having a new and unproven treatment
(Table 3: Quote 12).
Potential for false hopes and disappointments
The potential for unrealistic expectations around the impact
of SCT was raised as a concern by some participants
(Table 3: Quote 13). It was also acknowledged that if the
treatment did not work as expected that this would be “quite
a big blow” and a “disappointment” after going through the
process of deciding and then undergoing treatment (Table 3:
Quote 14).
Research during pregnancy
Participants acknowledged that research during pregnancy
needed to be “put together and very carefully, with careful
protocols and handled sensitively”, particularly if there was
an increased risk of miscarriage. However, no-one was
opposed to conducting research in pregnancy and the
importance of conducting research to “move new treatments
and therapies forward” was noted. Many participants com-
mented that if people were well informed of the risks and
any limitations of the intervention that it should be up to the
individual to choose whether to participate.
Decision making
Parents face a difﬁcult decision
Deciding whether to take part in the BOOSTB4 clinical trial
was acknowledged by all participants to be a difﬁcult
decision that would be “considered differently by every
family”. Many participants felt that deciding about SCT at
the time of diagnosis would be particularly difﬁcult as
parents are made vulnerable by their shock and grief and it
may be harder to absorb information at this time (Table 3:
Quote 15). Some participants also noted the added
responsibility of the decision because “a decision about
someone else’s life is a big decision”. Another key issue
was uncertainty around efﬁcacy and long-term outcomes
and the need to take a “leap of faith”. Decision making may
also be difﬁcult as it is hard to predict the impact of OI,
even when other family members are affected. Many par-
ticipants highlighted that previous experience may inﬂuence
decision making and that weighing up risks and beneﬁts
may be more difﬁcult for parents with no previous experi-
ence of OI (Table 3: Quote 16).
Decisions made during pregnancy or after the birth of the
child
When discussing the issues speciﬁc to decision making
in pregnancy, the risk of miscarriage was invariably
thought to be a major consideration for parents. Other
issues frequently discussed were the need to consider risks
for both baby and mother and time pressures, as preg-
nancy brings “a time limit and that sense of urgency with
making your decision”. Some health professionals and
patient advocates also spoke about the added difﬁculty of
weighing up termination of pregnancy when there was
an offer of an intervention. They thought that some
parents would opt for termination and “wouldn’t even
consider [SCT] because for them they don’t want to
take the risk of disability”, while other parents will be
more undecided about termination and the offer of an
intervention will add to the complexity of an already
“emotionally laden” decision.
Many participants thought that decision making after the
baby was born was likely to be “slightly easier” as there was
not a procedural risk to the health of child and the time
pressures of pregnancy are removed. They acknowledged,
however, that the other complexities of the decision
remained, and other factors may impact the decision. For
example, some participants noted that when the baby is
born, OI becomes much more real and you may be
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motivated to opt for SCT when the baby is in front of you
and you are dealing with multiple fractures.
Potential pressure to choose SCT
Participants were asked if they thought parents might feel
pressured to take part in the clinical trial. While it was
acknowledged that parents may feel pressure from health
professionals to participate, most felt that this would be very
dependent on the health professional and their approach to
explaining the clinical trial. Emotional pressures to accept
the offer of SCT were discussed by some participants. For
example, parents may place pressures on themselves to be
“good” parents and do everything they can to help the child
or they may be inﬂuenced by feelings of guilt for passing on
the gene. Emotional pressures were evident when some
participants in the patient and parent group described their
willingness to “do anything” to reduce the severity of the
condition (Table 3: Quote 17). Several participants com-
mented that when the choice is to do nothing or to do
something that could potentially help, it is very difﬁcult to
do nothing and that “it would be easy to think there’s only
one option if you’re kind of given the option of helping
your baby or not helping your baby”.
Practical considerations
Practical considerations raised included the need to travel to
a specialist centre to have SCT and for some follow-up
appointments. It was noted that it can be difﬁcult travelling
with a baby affected with OI and it can sometimes be dif-
ﬁcult for adults with OI to travel long distances. Issues such
as taking time off work to attend appointments and sorting
out childcare for siblings were also noted. The fact that SCT
would not be a one off intervention but may have to be
performed every six months was not seen as a barrier as this
was not dissimilar to treatment with bisphosphonates, with
which many families are familiar.
Information and support needs for decision making
Participants felt that information in plain language, emo-
tional support and time for reﬂection would make it possible
for parents to make an informed decision. Supporting par-
ents to make the best decision for their individual family
was a priority for health professionals. Many participants
highlighted the need for health professionals to be clear that
the treatment may not work and felt that a key component of
the discussion would be expectation setting. Several parti-
cipants spoke about how substantial support would be
needed for decision making and that counselling would be
required to work through the emotional aspects of the
decision and to “question and challenge” parental choices.
Many also felt that it would be important to speak to a
counsellor or nurse specialist who was independent of the
trial.
Many participants highlighted that counselling and sup-
port needs may differ where there is a family history of OI
compared to a new and unexpected OI diagnosis. Families
with no previous experience of OI may need much more
support and input from OI specialist teams and patient
groups to allow them to get a realistic understanding of
what OI would mean for their family. Partners of adults
with OI may also need this additional support and infor-
mation about the condition. In addition, some parents may
want to speak to their own OI clinician with whom they
have an existing relationship and have built up trust.
Discussion
As new approaches to treatments are developed, stakeholder
views must be considered to ensure acceptability and to
explore information and support needs for potential parti-
cipants of clinical trials and for future implementation. Most
participants in our study reported feeling positive about
SCT and the BOOSTB4 trial but also raised concerns about
possible risks and the complexity of decision making. These
views reﬂect those seen in other studies which report sta-
keholders holding strong, yet cautious, support for stem cell
research [13]. Offering SCT during pregnancy was valued
by participants as this would allow intervention before
fractures occur. Accordingly, many participants in the
patients and parents group said that they would consider
SCT during pregnancy, but some felt that they would not be
prepared to put the pregnancy at risk of miscarriage and
would wait until after the child was born to decide.
The potential clinical and psychosocial beneﬁts of SCT
cited by participants, where fewer fractures and less time in
hospital was anticipated to lead to more school and social
time and a more normal life, reﬂect research ﬁndings
exploring the experiences of children affected with OI. Two
recent systematic reviews found that the clinical features of OI
have a signiﬁcant impact on quality of life [14] and many
psychosocial implications such as feelings of isolation and
being different [15]. Potential psychosocial beneﬁts for par-
ents were also discussed and participants thought that redu-
cing OI severity would allow parents to view their child as
more robust, alleviating fear of fractures and giving con-
ﬁdence for handling their baby. Other studies have shown that
fear of fractures and the uncertainty of when the next fracture
could occur are a constant feature of family life when a child
has OI [16, 17], and parents face feelings of stress, help-
lessness, guilt, anxiety, depression and a lack of conﬁdence in
parenting skills [16, 18, 19]. The possibility of intervention at
the time of diagnosis was anticipated to bring hope to parents
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and similar psychological beneﬁts have been seen in studies
looking at motivators for parents participating in paediatric
research, for example parents considering research trials for
Duchenne muscular dystrophy (DMD) reported feeling opti-
mism and empowerment from potentially being able to
impact the disease course [20, 21].
Several factors combine to make decision making com-
plex for parents that could be offered SCT. Although par-
ticipants felt strongly that decision making would be
difﬁcult, they also thought that it would be possible to
support informed decision making. In a study looking at
views of a clinical trial of maternal gene therapy for severe
fetal growth restriction, women with a previous affected
pregnancy also noted the difﬁculty of decision making at
the time when a problem with the pregnancy was diagnosed
[22]. In common with this study, it was felt that women
would place themselves under emotional pressure to parti-
cipate in a trial that would help their baby, but they felt that
informed decisions would be possible with good informa-
tion and careful counselling [22]. Parents invited to parti-
cipate in research trials during pregnancy have previously
described limitations in consent procedures and lack of
information [23] and insufﬁcient time for discussion with
research staff [24]. In the paediatric research setting, parents
of children invited to take part in research wanted more
discussion time with researchers [20] and the importance of
expectation setting has been highlighted as parents had not
considered that the trial might fail [21]. Careful considera-
tion is needed to develop study materials and counselling
strategies. Suggestions for good practice are summarised in
Table 4.
For parents with no previous experience of OI, dealing
with a new and unexpected diagnosis of a rare condition
will add to the difﬁculty of making a decision about parti-
cipating in the BOOSTB4 clinical trial. In line with parti-
cipant views on diagnosis in this study, other qualitative
research with parents of children with OI shows that diag-
nosis can initially be a devastating experience and parents
often feel that more support and information is needed at
this time [18, 19]. Accordingly, the need for additional
support and more detailed information about the condition
for parents without previous experience of OI was noted by
participants in this study. Additional support requirements
from OI teams need to be considered when planning the
clinical trial.
The ethical issues associated with the medical use of
stem cells derived from fetal tissue have been debated in the
literature and highlighted in the media for many decades
[25, 26]. Several studies have looked at stakeholder views
and found varying viewpoints. In 1994 Anderson et al [27]
described a survey of 692 women, where 419 had never had
a termination, that found the majority (94%) supported the
use of fetal tissue in research. More recently a focus group
study with 41 women, 10 of whom had never had a ter-
mination, found concerns about donating fetal tissue for
research that included the potential for mishandling the
terminated fetus in the laboratory and the idea that some-
how the physical existence of the fetus would be reinstated
if the stem cells were used in research [28]. For a small
number of participants, the proposal to use MSCs that were
fetal in origin raised ethical concerns. For many, however,
this was not a barrier to the acceptability of SCT. Ulti-
mately, information about SCT must fully disclose the fetal
origin of the MSCs so that parents can make a decision in
line with their own ethical and moral values.
Limitations
Although the patient and parent group included individuals
with a wide variety of experiences of life with OI, including
differing OI severities and a range of ages, a key limitation
of the study was that the majority of participants in this
group were female, white British and well educated and this
may limit generalisability. Another consideration for gen-
eralisability is that we did not interview any parents that had
Table 4 Summary of good practice points when offering stem cell
transplantation to parents
Good practice points
Signiﬁcant support needed to help with decision making
Include both partners in the counselling
Allow time for discussion and time to go away and think
Provide good written information to take away
Provide carefully considered links to descriptions of OI
Diagnosis in pregnancy - explore the option to terminate and take
care with the timing of the SCT offer
Describe the commitment needed (e.g., number of appointments,
length of follow-up)
Be clear with expectation setting and be honest that outcomes are
uncertain
Supply details of previous research, including numbers previously
treated and case studies
Clear explanation of possible short and long-term side effects and
unanticipated adverse events
Clear explanation of procedural risks for baby and mother
Clearly state that the stem cells are fetal in origin
Discuss other options for treatment
Careful framing of SCT to avoid pressure to participate
Explore and mitigate possible pressures parents may place on
themselves to participate
Put families in touch with someone independent
Be aware that families faced with a new and unexpected diagnosis of
OI may need much more input from the OI specialist health
professionals and patient support groups
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chosen to have a termination when OI was diagnosed dur-
ing pregnancy. An important limitation was that all parti-
cipants were self-selected and there may be responder bias
towards people who hold strong pre-existing views
regarding SCT. As such, care must be taken in interpreting
the ﬁndings as they may not represent the wider population.
Very few differences in the individual themes and sub
themes that emerged were seen between the health profes-
sional, patient advocate and patient and parent groups,
which may be explained by parents and patients having
good medical knowledge about OI and that several parti-
cipants in the patient and parent group were health profes-
sionals themselves. In the future it will be important to
explore the experiences of parents who are offered SCT as
part of the BOOSTB4 trial and speak to people who both
accept and decline the invitation to participate.
Conclusion
Key stakeholders support the application of a clinical trial of
fetal MSC transplantation to treat severe OI administered
during pregnancy or shortly after birth. Using plain lan-
guage to explain SCT in a way that parents understand,
clear expectation setting, substantial psychological support
and time for reﬂection during the decision-making process
will be crucial to allow parents to make informed decisions
to take part in the BOOSTB4 clinical trial. Counselling and
support needs may be different for families with a history of
OI compared to families with a new and unexpected OI
diagnosis.
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